~ Buy the SIMBRINZA (brimonidine tartrate; brinzolamide) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR SIMBRINZA

All Clinical Trials for SIMBRINZA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01937299 ↗	Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®	Completed	Alcon Research	Phase 4	2013-10-01	The purpose of this study is to demonstrate the additive effect of brinzolamide 1%/brimonidine 0.2% (SIMBRINZA® suspension) in subjects with either open angle glaucoma or ocular hypertension who are currently on a prostaglandin analogue (PGA) monotherapy (TRAVATAN Z®).
NCT01937312 ↗	Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue	Completed	Alcon Research	Phase 4	2013-10-01	The purpose of this study is to demonstrate the additive effect of brinzolamide 1%/brimonidine 0.2% (SIMBRINZA® suspension) in subjects with either open angle glaucoma or ocular hypertension who are currently on a prostaglandin analogue (PGA) monotherapy.
NCT01978600 ↗	Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension	Completed	Alcon Research	Phase 4	2013-10-01	The purpose of this study is to evaluate intraocular pressure (IOP) over a 24-hour period using Simbrinza™ topical ophthalmic suspension.
NCT02167035 ↗	Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)	Completed	Allergan	Phase 4	2014-08-01	To compare Combigan Two Times Daily (BID) vs Simbrinza Three Times Daily (TID) in subjects currently being treated with Latanoprost for Open-Angle Glaucoma or Ocular Hypertension. Both of these drugs are currently FDA approved as combination therapy for patients with Open-Angle Glaucoma or Ocular Hypertension. The purpose of this clinical trial would be to assess which treatment, if either, is superior in lowering intraocular pressure (IOP). A secondary objective is to assess the tolerability of each drug.
NCT02167035 ↗	Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)	Completed	Cornerstone Health Care, PA	Phase 4	2014-08-01	To compare Combigan Two Times Daily (BID) vs Simbrinza Three Times Daily (TID) in subjects currently being treated with Latanoprost for Open-Angle Glaucoma or Ocular Hypertension. Both of these drugs are currently FDA approved as combination therapy for patients with Open-Angle Glaucoma or Ocular Hypertension. The purpose of this clinical trial would be to assess which treatment, if either, is superior in lowering intraocular pressure (IOP). A secondary objective is to assess the tolerability of each drug.

Clinical Trial Conditions for SIMBRINZA

Condition Name

Condition Name for SIMBRINZA
Intervention	Trials
Ocular Hypertension	7
Open-Angle Glaucoma	3
Glaucoma	3
Open Angle Glaucoma	2

Condition MeSH

Condition MeSH for SIMBRINZA
Intervention	Trials
Ocular Hypertension	7
Glaucoma	7
Glaucoma, Open-Angle	6
Hypertension	3

Clinical Trial Locations for SIMBRINZA

Trials by Country

Trials by Country for SIMBRINZA
Location	Trials
United States	5
Korea, Republic of	1

Trials by US State

Trials by US State for SIMBRINZA
Location	Trials
Texas	3
North Carolina	2

Clinical Trial Progress for SIMBRINZA

Clinical Trial Phase

Clinical Trial Phase for SIMBRINZA
Clinical Trial Phase	Trials
Phase 4	8
Phase 3	1

Clinical Trial Status

Clinical Trial Status for SIMBRINZA
Clinical Trial Phase	Trials
Completed	7
Recruiting	1
Terminated	1

Clinical Trial Sponsors for SIMBRINZA

Sponsor Name

Sponsor Name for SIMBRINZA
Sponsor	Trials
Alcon Research	6
Perrigo Company	1
Allergan	1

Sponsor Type

Sponsor Type for SIMBRINZA
Sponsor	Trials
Industry	9
Other	1